Principal Financial Group Inc Allovir, Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$0.64 - $0.78 $1,411 - $1,719	-2,205 Reduced 9.61%	20,732 $15,000
Q4 2023 Feb 07, 2024	SELL	$0.68 - $2.39 $1,721 - $6,049	-2,531 Reduced 9.94%	22,937 $15,000
Q3 2023 Nov 02, 2023	BUY	$2.15 - $3.64 $5,699 - $9,649	2,651 Added 11.62%	25,468 $54,000
Q2 2023 Aug 07, 2023	BUY	$3.17 - $5.82 $16,858 - $30,950	5,318 Added 30.39%	22,817 $77,000
Q1 2023 May 09, 2023	BUY	$3.94 - $7.05 $933 - $1,670	237 Added 1.37%	17,499 $68,000
Q4 2022 Feb 09, 2023	BUY	$4.7 - $9.98 $81,131 - $172,274	17,262 New	17,262 $88,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.